Business
Ventripoint Diagnostics Ltd. Announces Filing of Second Amended and Restated MD&A
(TheNewswire) Toronto, Canada – TheNewswire - October 13, 2021...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint Diagnostics Ltd. Announces Filing of Second Amended and Restated MD&A\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n Toronto, Canada –\n \n \n TheNewswire -\n \n \n October 13, 2021 – Ventripoint Diagnostics\nLtd. (“\n \n \n Ventripoint\n \n \n ” or the “\n \n \n Company\n \n \n ”)\n(TSXV:VPT\n \n \n )\n \n \n ,\n \n \n (\n \n \n OTC:VPTDF), announces that as a result\nof a review by staff of the Ontario Securities Commission\n(“\n \n \n OSC\n \n \n ”) it is issuing the following press release to clarify its\nprevious disclosure. The Company has filed a second amended and\nrestated management’s discussion and analysis for the three and six\nmonth period ended June 30, 2021 (the “\n \n \n Second Revised MD&A\n \n \n ”).\n \n \n \n \n The Second Revised MD&A was refiled to, among other\nthings, provide enhanced disclosure of the Company’s projects,\nplans, expenditures made and the timing and costs anticipated to\nadvance the Company’s projects to the next stage.  The Business\nObjectives and Milestones discussion in the Second Revised MD&A\nhas been revised to include details with respect to the Company’s\nsales efforts and strategy, General Electric  Healthcare\ncollaboration, VMS+4.0 timing, product design and development\nprograms, and commercialization.\n \n \n \n \n The revisions reflected in the Revised MD&A have\nbeen made at the request of OSC staff in connection with their review\nof the Company’s preliminary short form prospectus dated October 1,\n2021.\n \n \n \n \n ABOUT VENTRIPOINT DIAGNOSTICS\nLTD.\n \n \n \n \n Ventripoint has become an industry leader in the\napplication of AI (Artificial Intelligence) to echocardiography.\nVentripoint’s VMS products are powered by its proprietary KBR\ntechnology, which is the result of a decade of development and\nprovides accurate volumetric cardiac measurements equivalent to MRI.\nThis affordable, gold-standard alternative allows cardiologists\ngreater confidence in the management of their patients. Providing\nbetter care to patients serves as a springboard and basic standard for\nall of Ventripoint’s products that guide our future developments. In\naddition, VMS+ is versatile and can be used with all ultrasound\nsyst...